trial · primary record
Indoximod
Glioblastoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 130 |
| Primary completion | 2027-12-11 |
| Primary endpoint | 8-month iRANO-PFS (Progression-Free Survival, defined by immune-adapted iRANO criteria) |
| Registry ID | NCT04049669 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:52.070Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04049669
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Indoximod · compound